Nasdaq
$7.31▼ 0.88%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $99.6MShares out 13.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
13- 10.1After-hours26.10.02 05:05S-8Offering#●●●#●●●
IMMUNIC, INC.
Immunic, Inc. has filed a registration statement on Form S-8 to register an additional 1,300,000 shares of common stock for its 2026 Inducement Plan. This amendment is intended to provide equity-based compensation for new employees as part of the company's talent acquisition strategy.…more
$7.31-0.88%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.19Closed26.09.19 10:004Ownership
IMMUNIC, INC.
Insider Robert Thorvald Nagel of Immunic, Inc. reported changes in his beneficial ownership of securities effective September 16, 2026. This filing serves as a Form 4 statement regarding the insider's equity position.…more
$7.31-0.88%vs prev closeView filingShare - 9.18After-hours26.09.19 08:454Ownership
IMMUNIC, INC.
Biotechnology Value Fund and affiliated investment entities reported an increase in their shareholdings of IMMUNIC, INC. as of September 16, 2026. This filing is a Form 4 statement detailing the changes in beneficial ownership by major shareholders.…more
$7.31-0.88%vs prev closeView filingShare
12 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoPre-market26.10.21 20:12#●●●#●●●
Immunic Reports Positive Long-Term Data for Vidofludimus Calcium in Phase 2 MS Trial…more
Immunic announced that open-label extension data supports the durability of disability outcomes for its MS drug candidate. The results are based on ongoing Phase 2 trials, requiring further clinical validation for definitive market impact.…more
$7.31-0.88%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.7Pre-market26.10.07 21:07
●●●●●●●● ●●●●● ●●●●●●
Immunic announced that four abstracts regarding its lead investigational asset, vidofludimus calcium, have been accepted for presentation at the upcoming ACTRIMS-ECTRIMS meeting. This event focuses on sharing clinical and preclinical data, representing a standard scientific update rather than a material financial catalyst.…more
$7.31-0.88%vs prev closeShareBenzinga
1 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report